Counts, ScottRay, BalmikiMufson, Elliott J.Perez, Sylvia E.He, BinLahiri, Debomoy K.2016-02-052016-02-052014-07Counts, S., Ray, B., Mufson, E. J., Perez, S. E., He, B., & Lahiri, D. K. (2014). Intravenous Immunoglobulin (IVIG) treatment exerts antioxidant and neuropreservatory effects in preclinical models of Alzheimer’s disease. Journal of Clinical Immunology, 34(0 1), S80–S85. http://doi.org/10.1007/s10875-014-0020-9https://hdl.handle.net/1805/8263Intravenous immunoglobulin (IVIG) has shown limited promise so far in human clinical studies on Alzheimer's disease (AD), yet overwhelmingly positive preclinical work in animals and human brain cultures support the notion that the therapy remains potentially efficacious. Here, we elaborate on IVIG neuropreservation by demonstrating that IVIG protects human primary neurons against oxidative stress in vitro and that IVIG preserves antioxidant defense mechanisms in vivo. Based on these results, we propose the following translational impact: If the dosage and treatment conditions are adequately optimized, then IVIG treatment could play a significant role in preventing and/or delaying the progression of neurodegenerative diseases, such as AD. We suggest that IVIG warrants further investigation to fully exploit its potential as an anti-oxidant, neuroprotective and synapto-protecting agent.en-USPublisher PolicyAlzheimer Disease -- ImmunologyAmyloid beta-Protein Precursor -- GeneticsCell Survival -- Drug EffectsImmunoglobulins, Intravenous -- Administration & dosageMice, Inbred C57BLNeurogenic Inflammation -- ImmunologyArticle